9,761 Shares in McKesson Corporation $MCK Acquired by Ancora Advisors LLC

Key Points

• Ancora Advisors acquired 9,761 McKesson shares worth approximately $7.4 million, while several other institutional investors also initiated positions; institutions collectively own 85.07% of the company.
• McKesson exceeded quarterly expectations with $9.93 in EPS and $105.38 billion in revenue, while revenue increased 7.7% year over year. The company also raised its quarterly dividend from $0.82 to $0.94 per share.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and a $973.44 average price target, although insiders have sold roughly $18 million in stock over the past 90 days and valuation, drug-pricing pressure and expansion costs remain risks.

Ancora Advisors LLC purchased a new stake in McKesson Corporation (NYSE:MCK - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 9,761 shares of the company's stock, valued at approximately $7,375,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MCK. Delos Wealth Advisors LLC acquired a new position in McKesson in the second quarter valued at about $27,000. Primecap Management Co. CA acquired a new stake in McKesson during the 2nd quarter valued at $15,104,000. PDT Partners LLC bought a new position in McKesson in the 2nd quarter valued at $16,699,000. Canada Pension Plan Investment Board acquired a new position in McKesson in the second quarter worth $125,232,000. Finally, Osterweis Capital Management Inc. acquired a new position in McKesson in the second quarter worth $171,000. 85.07% of the stock is owned by institutional investors.

Insider Buying and Selling at McKesson

In other news, EVP Thomas L. Rodgers sold 699 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $735.27, for a total transaction of $513,953.73. Following the completion of the transaction, the executive vice president directly owned 2,268 shares in the company, valued at $1,667,592.36. This represents a 23.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Brian S. Tyler sold 8,463 shares of the business's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the transaction, the chief executive officer owned 5,919 shares in the company, valued at approximately $4,697,081.64. The trade was a 58.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,111 shares of company stock valued at $18,011,274 over the last ninety days. 0.06% of the stock is currently owned by company insiders.

McKesson Stock Performance

Shares of McKesson stock opened at $904.31 on Wednesday. The firm has a fifty day moving average of $825.22 and a two-hundred day moving average of $844.60. The stock has a market capitalization of $105.43 billion, a price-to-earnings ratio of 24.20, a PEG ratio of 1.72 and a beta of 0.30. McKesson Corporation has a 52 week low of $673.38 and a 52 week high of $999.00.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 EPS for the quarter, beating analysts' consensus estimates of $9.56 by $0.37. The company had revenue of $105.38 billion during the quarter, compared to analysts' expectations of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.McKesson's revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, research analysts forecast that McKesson Corporation will post 44.65 EPS for the current fiscal year.

McKesson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $3.76 annualized dividend and a yield of 0.4%. This is an increase from McKesson's previous quarterly dividend of $0.82. McKesson's payout ratio is presently 8.78%.

Analyst Ratings Changes

A number of analysts have recently weighed in on MCK shares. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $875.00 target price on shares of McKesson in a research note on Friday, May 8th. Barclays upped their price target on shares of McKesson from $925.00 to $1,000.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 19th. JPMorgan Chase & Co. lowered their price objective on shares of McKesson from $1,107.00 to $1,015.00 and set an "overweight" rating for the company in a research report on Friday, May 8th. Royal Bank Of Canada assumed coverage on shares of McKesson in a research note on Wednesday, August 19th. They issued a "sector perform" rating and a $845.00 target price for the company. Finally, Weiss Ratings lowered shares of McKesson from a "buy (b)" rating to a "buy (b-)" rating in a research report on Tuesday, July 7th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $973.44.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson agreed to acquire Precision Medicine Group for approximately $2.25 billion. The transaction would add clinical research, consulting and biopharma commercialization capabilities to McKesson’s oncology-focused business, broadening its exposure to higher-growth healthcare services. Reuters article about McKesson's Precision Medicine acquisition
• Positive Sentiment: McKesson raised its fiscal 2027 earnings outlook as oncology demand, GLP-1 volumes and specialty pharmaceutical distribution accelerate. The higher guidance reinforces expectations for double-digit earnings growth and supports investor confidence in the company’s growth strategy. McKesson FY2027 guidance article
• Positive Sentiment: Short interest fell 33% to about 2.42 million shares as of August 14, representing roughly 2.1% of shares outstanding and 2.2 days of average trading volume. The decline suggests reduced bearish positioning and may provide additional support for the stock.
• Neutral Sentiment: Healthcare stocks broadly advanced late Tuesday, giving McKesson a favorable sector backdrop. However, sector-wide gains do not necessarily reflect company-specific fundamentals. Healthcare sector update
• Negative Sentiment: Analysts caution that McKesson’s premium valuation leaves less room for execution setbacks. Drug-pricing pressure, potential policy changes and cash-flow demands associated with expansion and acquisitions remain risks to the investment thesis. McKesson valuation analysis

McKesson Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source